Senolytic therapy of PDAC
Peer-Reviewed Publication
Updates every hour. Last Updated: 22-Jun-2026 07:16 ET (22-Jun-2026 11:16 GMT/UTC)
How do blood vessels stay strong, flexible, and responsive to the body’s changing need for oxygen and nutrients? The answer lies not only in biology—but also in physics. Researchers at Åbo Akademi University (Finland) and the InFLAMES Flagship have uncovered new molecular pathways that allow blood vessel cells to sense and respond to the mechanical forces generated by blood flow. The findings open new possibilities for understanding—and potentially influencing—vascular health in cardiovascular disease, regenerative medicine, and cancer therapy.
For decades, T cells have been known as key players in the adaptive immune system that eliminate abnormal cells via cytotoxicity at the immunological synapse, while phagocytosis—the process of engulfing and destroying foreign or abnormal cells—was thought to be exclusive to professional phagocytes like macrophages and dendritic cells. Now, a groundbreaking study led by Dr. Ning (Jenny) Jiang from the University of Pennsylvania has overturned this long-held belief, revealing that T cells can perform antigen-specific phagocytosis directly through TCR-pMHC (T cell receptor-peptide major histocompatibility complex) recognition. The research, published in the open-access journal Mechanobiology in Medicine, not only expands the functional repertoire of T cells but also paves the way for innovative T cell-based immunotherapies, especially for solid tumors that currently pose major challenges to treatment.
People with limited English are significantly more likely to understand the true aim of cancer treatment when given a bilingual consent form, with understanding rising from 35% to 60%, a new study finds.
Sylvester Cancer's March tip sheet contains a variety of cancer-related story ideas including colorectal cancer prevention, exercise during chemotherapy for breast cancer, colorectal and pancreatic cancer immunotherapy research awards, the 2026 Dolphins Cancer Challenge and more.
An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found.
Experimental cream that blocks enzyme may offer a precise, better‑tolerated path to prevent and treat cutaneous squamous cell carcinoma
Results from a global phase 3 clinical trial led by investigators at Mass General Brigham show that the medication romiplostim can effectively prevent chemotherapy from destroying platelet-producing bone marrow cells, a common complication known as chemotherapy-induced thrombocytopenia. Romiplostim boosts the bone marrow's ability to withstand the assault of chemotherapy so that recipients of the medication can continue to make platelets that are needed to prevent bleeding.